Simpson, Eric L.
de Bruin-Weller, Marjolein
Hong, H. Chih-ho
Staumont-Sallé, Delphine
Blauvelt, Andrew
Eyerich, Kilian
Gooderham, Melinda
Shahriari, Mona
Mallbris, Lotus
Atwater, Amber Reck
Rueda, Maria Jose
Ding, Yuxin
Liu, Zhuqing
Agell, Helena
Silverberg, Jonathan I.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01158-4
Documents that mention this clinical trial
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01158-4
Article History
Received: 16 February 2024
Accepted: 3 April 2024
First Online: 3 May 2024
Declarations
:
: Eric Simpson: reports personal fees from AbbVie, Amgen, Arcutis, Areteia Therapeutics,, Bristol Myers Squibb – BMS, CorEvitas, Corvus, Dermira, Eli Lilly, Evelo Biosciences, FIDE, Forte Bio RX, Galderma, GlaxoSmithKline, Gilead Sciences, Impetus Healthcare, Incyte, Innovaderm Reche, Janssen, Johnson & Johnson, Kyowa Kirin Pharmaceutical Development, Leo, Merck, MJH holding (4/29/2021), NUMAB Therapeutics AG, Pfizer, Physicians World LLC, PRImE, Recludix Pharma, Regeneron, Roivant, Sanofi-Genzyme, Trevi therapeutics, Valeant; and grants (or serves as Principal investigator role) for AbbVie, Acrotech, Amgen, Arcutis, ASLAN, Castle, CorEvitas, Dermavant, Dermira, Incyte, Lilly, Kymab, Kyowa Kirin, National Jewish Health, Leo, Pfizer, Regeneron, Sanofi, Target, VeriSkin. Marjolein de Bruin-Weller: reports being a consultant, advisory board member, and/or speaker for AbbVie, Almirall, Aslan, Amgen, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi. H. Chih-ho Hong has been an investigator for and/or received honorarium from AbbVie, Amgen, Arcutis, Bausch Health, Boehringer-Ingelheim, Bristol-Meyers Squibb, Celgene, Cutanea, Dermira, Dermavant Sciences, DS Biopharma, Eli Lilly and Company, Galderma S.A., GSK, Incyte, Janssen, LEO Pharma, MedImmune, Merck, Mirimar, Novartis, Pfizer, Regeneron Pharmaceuticals, Roche, Sanofi-Genzyme, and UCB. Delphine Staumont-Sallé is speaker and/or advisory board member and/or investigator for AbbVie, Almirall S.A., Amgen, AstraZeneca, Eli Lilly and Company, Galderma S.A., Janssen, LEO Pharma, Novartis, Pfizer, Sanofi-Regeneron, and UCB. Andrew Blauvelt: has served as a speaker (received honoraria) for Eli Lilly and Company, Pfizer, and UCB, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Apogee, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, CTI BioPharma, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Lipidio, Microbion, Merck, Monte Rosa Therapeutics, Nektar, Novartis, Overtone Therapeutics, Paragon, Pfizer, Q32 Bio, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, Takeda, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Ventyx, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Allakos, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, DermBiont, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharma, Takeda, UCB Pharma, and Ventyx. Kilian Eyerich is speaker and/or advisory board member for AbbVie, Almirall S.A., Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, Pfizer, Sanofi, and UCB Pharma and holds shares of Dermagnostix and Dermagnostix R&D. Melinda Gooderham: has been an investigator, speaker and/or advisor for: AbbVie, Acelyrin, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Cara, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Tarsus, Takeda, UCB, Union and Ventyx. Mona Shahriari reports consulting for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Cara, Dermavant, Incyte, Janssen, Leo Pharma, Lilly USA, Novartis, Sanofi-Genzyme, Regeneron, UCB Disease State: Psoriasis, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa; being a speaker for Abbvie, Arcutis, Bristol Myers Squibb, Lilly USA, Janssen, Dermavant, Leo Pharma, Pfizer, Sanofi-Genzyme, Regeneron, UCB Disease State: Psoriasis, Atopic Dermatitis, Alopecia Areata, Prurigo Nodularis and with regard to publications reports being consultant (honoraria) for AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Janssen, Leo Pharma, Lilly USA, Novartis, Ortho Dermatologics, Sanofi-Genzyme, Regeneron, UCB; being a speaker for Abbvie, Arcutis, Bristol Myers Squibb, Lilly USA, Janssen, Dermavant, Leo Pharma, Pfizer, UCB; and being an Investigator for AbbVie, CorEvitas Psoriasis and Atopic Dermatitis Registry, Dermira, Cara, Dermavant, Novartis, Union, Mindera. Lotus Mallbris, Amber Reck Atwater, Maria Jose Rueda, Yuxin Ding, and Zhuqing Liu are employees and stockholders of Eli Lilly and Company. Helena Agell is an employee of Almirall S.A. Jonathan I Silverberg: has received honoraria as a consultant and/or advisory board member for Abbvie, Aldena, Amgen, AObiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Bristell-Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Invea, Kiniksa, Leo Pharma, My-Or Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union, UpToDate; speaker for Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; institution received grants from Galderma, Incyte, Pfizer.
: Studies were conducted in accordance with the Declaration of Helsinki and the International Council for the Harmonization of Good Clinical Practice Guideline and approved by individual institutional review boards at each participating study center. All patients provided written informed consent. Studies are registered at ClinicalTrials.gov: ADvocate 1 (NCT04146363) and ADvocate2 (NCT04178967).